Go to Contents

Collaborative research in the application of the latest technologies in IT, BT and NT World Leader in Convergence Technology Research

Current location page

> RESEARCH > Institute of Bio Convergence

Institute of Bio Convergence

Sunghwa Choe/ Director homepage  send email
  • Influenza HA antigen, CRISPR/Cas9 genome editing, plant factory

  • To apply CRISPR/Cas9 genome editing technology to the model plant Arabidopsis thaliana for establishment of influenza HA antigen production in a plant factory

Research Areas
  • Genome editing, recombinant protein expression, influenza HA antigen production and efficacy test, cultivation in plant factory

Contents of research
  • Screening for the most efficient Arabidopsis ecotypes for producing influenza HA antigens and establishing procedures for the large scale agrobacterium mediated HA transient expression in plant
  • Optimizing the growth of various Arabidopsis ecotypes through hydrophonics in a plant factory
  • Cloning and mutant screening for editing Arabidopsis glycosyltransferase genes via CRISPR/Cas9 system
  • Cloning influenza HA antigen genes, establishing a suitable RNA viral vector system for recombinant protein expression in plant and testing the efficacy

Result & Expected effect
  • Currently, we are examining various Arabidopsis ecotypes and the respective protein yields for the optimum production of influenza HA antigens in plant.
  • Improving protein yields through HA gene synthesis and cloning followed by testing the optimum growth condition in a plant factory are in progress.
  • Generating arabidopsis glycosyltransferase mutants using the CRISPR/Cas9 system, and screening for the mutants with desirable protein production traits are constantly being performed.
  • Also, the efficacy of recombinant proteins are examined in vivo.

Go to page top